Filing Flows › Mangoceuticals (MGRX) › Q2 2026
Mangoceuticals (MGRX) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 13, 2026
Mangoceuticals (MGRX) reported revenue of $69K for the second quarter 2026 (Q2 2026), -59% from a year earlier and +1% from the quarter before.
Mangoceuticals, Q2 2026: revenue $69K (-59% year over year), net loss $1.3M, operating cash flow −$261K. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $69K | +1% | -59% |
| Operating profit | −$1.0M | — | — |
| Net earnings | −$1.3M | — | — |
| Operating cash flow | −$261K | — | — |
What changed
Revenue was $69K in Q2 2026, down 59% year over year and up 1% from the previous quarter.
Gross margin was 64.3%, up 10.8 points from Q2 2025. Operating costs exceeded revenue by $1.0M, an operating margin of -1502.5%. Operating expenses fell 80% while revenue fell 59%. The fastest-growing cost line was Sales & marketing (+17%). The quarter ended with a net loss of $1.3M, narrower than the previous quarter's $3.4M loss. Minority interests bore $0K of it: to shareholders the quarter was a loss of $1.3M.
Operating cash flow was −$261K. Non-cash charges added back $280K of depreciation and amortization and $12K of share-based compensation. Working capital and other items added $760K.
Questions
What was Mangoceuticals' revenue in the second quarter 2026?
Mangoceuticals (MGRX) reported revenue of $69K for the second quarter 2026 (Q2 2026), -59% from a year earlier and +1% from the quarter before.
Source: Mangoceuticals 10-Q on SEC EDGAR.